Bellevue Group AG Sells 106,007 Shares of Privia Health Group, Inc. (NASDAQ:PRVA)

Bellevue Group AG lessened its holdings in Privia Health Group, Inc. (NASDAQ:PRVA - Free Report) by 10.0% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 953,164 shares of the company's stock after selling 106,007 shares during the period. Bellevue Group AG owned 0.79% of Privia Health Group worth $18,634,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in PRVA. Rhumbline Advisers raised its stake in Privia Health Group by 1.3% during the 4th quarter. Rhumbline Advisers now owns 287,200 shares of the company's stock valued at $5,615,000 after purchasing an additional 3,658 shares during the period. Nordea Investment Management AB raised its position in shares of Privia Health Group by 33.1% during the fourth quarter. Nordea Investment Management AB now owns 349,773 shares of the company's stock valued at $6,953,000 after buying an additional 86,910 shares during the last quarter. Franklin Resources Inc. lifted its holdings in shares of Privia Health Group by 2.2% in the third quarter. Franklin Resources Inc. now owns 1,300,240 shares of the company's stock worth $23,092,000 after buying an additional 28,480 shares in the last quarter. Barclays PLC boosted its position in shares of Privia Health Group by 240.3% during the third quarter. Barclays PLC now owns 224,018 shares of the company's stock worth $4,079,000 after acquiring an additional 158,188 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its stake in Privia Health Group by 8.4% during the third quarter. JPMorgan Chase & Co. now owns 188,384 shares of the company's stock valued at $3,430,000 after acquiring an additional 14,641 shares in the last quarter. 94.48% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

PRVA has been the subject of several research reports. Truist Financial increased their price objective on shares of Privia Health Group from $27.00 to $28.00 and gave the company a "buy" rating in a report on Thursday, April 10th. JMP Securities restated a "market outperform" rating and set a $29.00 price target on shares of Privia Health Group in a report on Monday, April 28th. Piper Sandler upped their price objective on Privia Health Group from $25.00 to $40.00 and gave the stock an "overweight" rating in a report on Friday, February 28th. Barclays raised their target price on shares of Privia Health Group from $21.00 to $23.00 and gave the company an "equal weight" rating in a report on Thursday, April 10th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $30.00 price objective on shares of Privia Health Group in a research report on Thursday, April 10th. One research analyst has rated the stock with a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $27.38.

Insider Buying and Selling

In other Privia Health Group news, CEO Parth Mehrotra sold 15,100 shares of the business's stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $23.33, for a total value of $352,283.00. Following the completion of the sale, the chief executive officer now directly owns 454,281 shares of the company's stock, valued at $10,598,375.73. The trade was a 3.22 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO David Mountcastle sold 3,445 shares of the firm's stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $23.33, for a total transaction of $80,371.85. Following the transaction, the chief financial officer now directly owns 176,231 shares in the company, valued at approximately $4,111,469.23. This trade represents a 1.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 34,484 shares of company stock valued at $799,163. Insiders own 10.70% of the company's stock.

Privia Health Group Price Performance

Shares of NASDAQ:PRVA traded down $0.26 during trading hours on Tuesday, hitting $22.72. 427,909 shares of the company's stock traded hands, compared to its average volume of 767,164. The firm has a market capitalization of $2.76 billion, a P/E ratio of 227.22, a price-to-earnings-growth ratio of 3.47 and a beta of 0.87. The business has a fifty day moving average price of $23.42 and a 200-day moving average price of $22.16. Privia Health Group, Inc. has a 1 year low of $15.92 and a 1 year high of $26.04.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.